These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22553112)

  • 1. Outcome of fibrillary glomerulonephritis.
    Kalbermatter SA; Marone C; Casartelli D; Hausberg M; Banfi G; Mihatsch M; Dickenmann M
    Swiss Med Wkly; 2012; 142():w13578. PubMed ID: 22553112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients.
    Javaugue V; Karras A; Glowacki F; McGregor B; Lacombe C; Goujon JM; Ragot S; Aucouturier P; Touchard G; Bridoux F
    Am J Kidney Dis; 2013 Oct; 62(4):679-90. PubMed ID: 23759297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis.
    Zäuner I; Bach D; Braun N; Krämer BK; Fünfstück R; Helmchen U; Schollmeyer P; Böhler J
    Am J Kidney Dis; 2002 Jan; 39(1):28-35. PubMed ID: 11774098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features.
    Rosenstock JL; Markowitz GS; Valeri AM; Sacchi G; Appel GB; D'Agati VD
    Kidney Int; 2003 Apr; 63(4):1450-61. PubMed ID: 12631361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary glomerulonephritis: an update on renal survival and determinants of progression.
    Moranne O; Watier L; Rossert J; Stengel B;
    QJM; 2008 Mar; 101(3):215-24. PubMed ID: 18245806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous "pulse" cyclophosphamide therapy of crescentic glomerulonephritis.
    Kunis CL; Kiss B; Williams G; D'Agati V; Appel GB
    Clin Nephrol; 1992 Jan; 37(1):1-7. PubMed ID: 1541058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?
    Caliskan Y; Torun ES; Tiryaki TO; Oruc A; Ozluk Y; Akgul SU; Temurhan S; Oztop N; Kilicaslan I; Sever MS
    Am J Nephrol; 2017; 46(2):96-107. PubMed ID: 28700996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab treatment for fibrillary glomerulonephritis.
    Hogan J; Restivo M; Canetta PA; Herlitz LC; Radhakrishnan J; Appel GB; Bomback AS
    Nephrol Dial Transplant; 2014 Oct; 29(10):1925-31. PubMed ID: 24867652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney biopsy results versus clinical parameters on mortality and ESRD progression in 2687 patients with glomerulonephritis.
    Haider DG; Masghati S; Goliasch G; Mouhieddine M; Wolzt M; Fuhrmann V; Hörl WH; Kaider A; Soleiman A
    Eur J Clin Invest; 2014 Jun; 44(6):578-86. PubMed ID: 24749685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of sex in primary glomerulonephritis.
    Cattran DC; Reich HN; Beanlands HJ; Miller JA; Scholey JW; Troyanov S;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2247-53. PubMed ID: 18182409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glomerular deposition disease, regarding a case of fibrillary glomerulonephritis].
    Cantillo Jde J; López Rdel P; Andrade RE
    Biomedica; 2009 Dec; 29(4):539-46. PubMed ID: 20440452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Indication Biopsies ≥5 Years After Kidney Transplant: A Single-Center Experience.
    Tatar E; Simsek C; Tasli F; Cayhan VK; Karatas M; Uslu A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):265-268. PubMed ID: 28260483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.
    Aaltonen S; Honkanen E
    Nephrol Dial Transplant; 2011 Sep; 26(9):2871-7. PubMed ID: 21427071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
    Andreiana I; Stancu S; Avram A; Taran L; Mircescu G
    BMC Nephrol; 2015 Jun; 16():90. PubMed ID: 26123651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.
    Mallett A; Tang W; Hart G; McDonald SP; Hawley CM; Badve SV; Boudville N; Brown FG; Campbell SB; Clayton PA; Johnson DW
    Am J Nephrol; 2015; 42(3):177-84. PubMed ID: 26418732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
    du Buf-Vereijken PW; Branten AJ; Wetzels JF;
    Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early initiation of immunosuppressive treatment in membranous nephropathy patients.
    Chan CK; Lai TS; Chen PM; Chou YH; Wu CF; Chiu YL; Chiang WC; Chen YM; Chu TS; Wu KD
    J Formos Med Assoc; 2017 Apr; 116(4):266-275. PubMed ID: 28202222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease.
    Ekart R; Ferjuc A; Furman B; Gerjevič Š; Bevc S; Hojs R
    Ther Apher Dial; 2013 Aug; 17(4):363-7. PubMed ID: 23931872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study.
    Manno RL; Seo P; Geetha D
    BMC Nephrol; 2015 Jun; 16():88. PubMed ID: 26108549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.